KR20140113688A - 치환 페닐아졸 유도체 - Google Patents

치환 페닐아졸 유도체 Download PDF

Info

Publication number
KR20140113688A
KR20140113688A KR1020147019737A KR20147019737A KR20140113688A KR 20140113688 A KR20140113688 A KR 20140113688A KR 1020147019737 A KR1020147019737 A KR 1020147019737A KR 20147019737 A KR20147019737 A KR 20147019737A KR 20140113688 A KR20140113688 A KR 20140113688A
Authority
KR
South Korea
Prior art keywords
mmol
added
solution
mixture
reference example
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147019737A
Other languages
English (en)
Korean (ko)
Inventor
시게오 야마노이
히데노리 나미키
유이치 오치아이
마도카 호시노
고지 마츠모토
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20140113688A publication Critical patent/KR20140113688A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020147019737A 2012-01-18 2013-01-17 치환 페닐아졸 유도체 Withdrawn KR20140113688A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2012-007840 2012-01-18
JP2012007840 2012-01-18
PCT/JP2013/050710 WO2013108800A1 (ja) 2012-01-18 2013-01-17 置換フェニルアゾール誘導体

Publications (1)

Publication Number Publication Date
KR20140113688A true KR20140113688A (ko) 2014-09-24

Family

ID=48799224

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147019737A Withdrawn KR20140113688A (ko) 2012-01-18 2013-01-17 치환 페닐아졸 유도체

Country Status (21)

Country Link
US (3) US9233958B2 (cg-RX-API-DMAC10.html)
EP (2) EP3009433B1 (cg-RX-API-DMAC10.html)
JP (2) JP6104181B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140113688A (cg-RX-API-DMAC10.html)
CN (1) CN104159892A (cg-RX-API-DMAC10.html)
AU (1) AU2013210394A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014017656A2 (cg-RX-API-DMAC10.html)
CA (1) CA2861847A1 (cg-RX-API-DMAC10.html)
CO (1) CO7020920A2 (cg-RX-API-DMAC10.html)
ES (2) ES2640667T3 (cg-RX-API-DMAC10.html)
HK (2) HK1200824A1 (cg-RX-API-DMAC10.html)
IL (1) IL233682A0 (cg-RX-API-DMAC10.html)
IN (1) IN2014MN01442A (cg-RX-API-DMAC10.html)
MX (1) MX2014008790A (cg-RX-API-DMAC10.html)
NZ (1) NZ627303A (cg-RX-API-DMAC10.html)
PH (1) PH12014501646A1 (cg-RX-API-DMAC10.html)
RU (1) RU2014133738A (cg-RX-API-DMAC10.html)
SG (1) SG11201404026SA (cg-RX-API-DMAC10.html)
TW (1) TWI551590B (cg-RX-API-DMAC10.html)
WO (1) WO2013108800A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201405108B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1200824A1 (en) 2012-01-18 2015-08-14 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
EP3766879A1 (en) * 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CN111388471B (zh) * 2020-03-03 2021-01-12 牡丹江医学院 一种治疗胆囊炎的药物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
BRPI0616465A2 (pt) * 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica
GB0606913D0 (en) * 2006-04-06 2006-05-17 Prosidion Ltd Compounds
NZ571869A (en) * 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
KR101536021B1 (ko) 2007-10-16 2015-07-10 다이이찌 산쿄 가부시키가이샤 피리미딜 인돌린 화합물
EP2241558A1 (en) 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
WO2010119881A1 (ja) 2009-04-15 2010-10-21 第一三共株式会社 インドリン化合物
BR112012002293A2 (pt) * 2009-08-05 2016-06-14 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso do composto
BR112012002311A2 (pt) * 2009-08-05 2016-05-31 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso do composto.
SG189320A1 (en) * 2010-10-14 2013-05-31 Daiichi Sankyo Co Ltd Acylbenzene derivative
PH12014500251A1 (en) 2011-07-29 2014-03-17 Daiichi Sankyo Co Ltd N-hetero-ring-substituted amide derivative
HK1200824A1 (en) 2012-01-18 2015-08-14 Daiichi Sankyo Company, Limited Substituted phenylazole derivative

Also Published As

Publication number Publication date
RU2014133738A (ru) 2016-03-10
HK1220448A1 (en) 2017-05-05
JP2017052800A (ja) 2017-03-16
NZ627303A (en) 2015-11-27
JP6104181B2 (ja) 2017-03-29
ES2602962T3 (es) 2017-02-23
BR112014017656A2 (pt) 2017-06-27
JPWO2013108800A1 (ja) 2015-05-11
EP2805941A4 (en) 2015-08-05
ES2640667T3 (es) 2017-11-03
US20160090375A1 (en) 2016-03-31
CA2861847A1 (en) 2013-07-25
SG11201404026SA (en) 2014-11-27
MX2014008790A (es) 2014-10-13
TWI551590B (zh) 2016-10-01
US9233958B2 (en) 2016-01-12
AU2013210394A2 (en) 2014-10-16
EP2805941B1 (en) 2016-08-17
PH12014501646A1 (en) 2014-10-13
US20140357675A1 (en) 2014-12-04
TW201335141A (zh) 2013-09-01
US9725438B2 (en) 2017-08-08
HK1200824A1 (en) 2015-08-14
CO7020920A2 (es) 2014-08-11
EP3009433A1 (en) 2016-04-20
ZA201405108B (en) 2015-10-28
IL233682A0 (en) 2014-09-30
CN104159892A (zh) 2014-11-19
IN2014MN01442A (cg-RX-API-DMAC10.html) 2015-07-03
WO2013108800A1 (ja) 2013-07-25
AU2013210394A1 (en) 2014-08-14
US20160081993A1 (en) 2016-03-24
EP3009433B1 (en) 2017-06-21
EP2805941A1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
US8354398B2 (en) Substituted isoxazole compounds
US20120225878A1 (en) Compounds
US20210261535A1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
US20250154115A1 (en) Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof
US9725438B2 (en) Substituted phenylazole derivative
KR20170103803A (ko) 요산 수준의 저감을 위한 이작용성 화합물 및 용도
KR101829086B1 (ko) 아실벤젠 유도체
EP2463279B1 (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
US8754112B2 (en) Sulfone derivative
EP2738168B1 (en) N-hetero-ring-substituted amide derivative
WO2025015420A1 (en) Novel fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
HK1171011B (en) Sulfone derivative
HK1198033B (en) N-hetero-ring-substituted amide derivative
NZ620339B2 (en) N-hetero-ring-substituted amide derivative
HK1171010B (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
WO2011105099A1 (ja) 新規な4-アルコキシピリミジン構造を有する化合物及びこれを含有する医薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140716

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid